High-dose oral vitamin D(3) supplementation in the elderly

Department of Medicine, University of Auckland, Auckland, New Zealand.
Osteoporosis International (Impact Factor: 4.17). 12/2008; 20(8):1407-15. DOI: 10.1007/s00198-008-0814-9
Source: PubMed

ABSTRACT Daily dosing with vitamin D often fails to achieve optimal outcomes, and it is uncertain what the target level of 25-hydroxyvitamin D should be. This study found that large loading doses of vitamin D(3) rapidly and safely normalize 25OHD levels, and that monthly dosing is similarly effective after 3-5 months. With baseline 25OHD > 50 nmol/L, vitamin D supplementation does not reduce PTH levels.
There is concern that vitamin D supplementation doses are frequently inadequate, and that compliance with daily medication is likely to be suboptimal.
This randomized double-blind trial compares responses to three high-dose vitamin D(3) regimens and estimates optimal 25-hydroxyvitamin D (25OHD) levels, from changes in parathyroid hormone (PTH), and procollagen type I amino-terminal propeptide (P1NP) in relation to baseline 25OHD. Sixty-three elderly participants were randomized to three regimens of vitamin D supplementation: a 500,000-IU loading dose; the loading dose plus 50,000 IU/month; or 50,000 IU/month.
The Loading and Loading + Monthly groups showed increases in 25OHD of 58 +/- 28 nmol/L from baseline to 1 month. Thereafter, levels gradually declined to plateaus of 69 +/- 5 nmol/L and 91 +/- 4 nmol/l, respectively. In the Monthly group, 25OHD reached a plateau of ~80 +/- 20 nmol/L at 3-5 months. There were no changes in serum calcium concentrations. PTH and P1NP were only suppressed by vitamin D treatment in those with baseline 25OHD levels <50 and <30 nmol/L, respectively.
Large loading doses of vitamin D(3) rapidly and safely normalize 25OHD levels in the frail elderly. Monthly dosing is similarly effective and safe, but takes 3-5 months for plateau 25OHD levels to be reached.

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Research into vitamin D has revealed the important role it plays in a variety of biologic functions. Despite this importance, vitamin D deficiency remains one of the most underdiagnosed conditions in the world. Although no evidence exists that athletes have a higher daily requirement than the general population, vitamin D deficiency in athletic individuals has been linked to decreased physical performance and a predisposition to stress fractures. Research investigating ergogenic effects of direct vitamin D supplementation in non-deficient athletes has yet to be performed. This review discusses the current evidence on the effects of vitamin D in athletes, along with recommended strategies for the correction of deficient states.
    The Physician and sportsmedicine 09/2012; 40(3):26-31. DOI:10.3810/psm.2012.09.1977 · 1.49 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The north–south geographical gradient of inflammatory bowel disease (IBD) prevalence, its epidemiology, the genetic association of vitamin D receptor polymorphisms, and results in animal models suggest that vitamin D plays an important role in the pathogenesis of IBD. The purpose of this review was to critically appraise the effectiveness and safety of vitamin D therapy in patients with IBD. MEDLINE, Scopus and Google Scholar were searched from inception to May 20, 2014 using the terms ‘Crohn’s disease’, ‘ulcerative colitis’ and ‘vitamin D’. Results: Vitamin D deficiency is common in patients with IBD. Limited clinical data suggest an association between low vitamin D concentration and increased disease activity in both ulcerative colitis (UC) and Crohn’s disease (CD). To date, only two small open label trials and one randomized controlled trial have shown a positive effect of vitamin D supplementation on disease activity in patients with CD; no effect has been shown for UC. An optimal vitamin D supplementation protocol for patients with IBD remains undetermined, but targeting serum 25-hydroxy vitamin D [25(OH)D] levels between 30 and 50 ng/mL appears safe and may have benefits for IBD disease activity. Depending on baseline vitamin D serum concentration, ileal involvement in CD, body mass index, and perhaps smoking status, daily vitamin D doses between 1800–10,000 international units/day are probably necessary. Increasing preclinical and clinical evidence suggests a role for vitamin D deficiency in the development and severity of IBD. The possible therapeutic role of vitamin D in patients with IBD merits continued investigation.
    Journal of Crohn s and Colitis 01/2014; 9(2):198-209. DOI:10.1093/ecco-jcc/jju004 · 3.56 Impact Factor
  • Osteoporosis International 01/2015; DOI:10.1007/s00198-015-3031-3 · 4.17 Impact Factor


Available from